Announcements Trials
Browse Landscape

Phase

Phase 2 32Phase 3 5Phase 1 5Phase 1/2 3Phase EARLY_PHASE1 1Phase 4 1Phase 2/3 1

Status

Not yet recruiting 2Recruiting 1

Sponsor Class

INDUSTRY 11OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 3Neoplasms, Plasma Cell 1

Interventions

Cyclophosphamide 250Radiotherapy 172pembrolizumab 155Carboplatin 147Gemcitabine 139Nivolumab 135Paclitaxel 129Dexamethasone 118Cisplatin 118fludarabine 115Rituximab 104Lenalidomide 103Bevacizumab 99Docetaxel 97Capecitabine 97fludarabine phosphate 92Temozolomide 89Cytarabine 89Oxaliplatin 87Etoposide 82Filgrastim 77Irinotecan 73Doxorubicin 73venetoclax 70Peripheral Blood Stem Cell Transplantation 68Fluorouracil 68Radiosurgery 66Melphalan 66Everolimus 66Bortezomib 66

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × OTHER × isatuximab × Clear all
NCT07601100 2026-06-01

IsaIberVD

Dana-Farber Cancer Institute

Phase 1/2 Not yet recruiting
88 enrolled
Plasma cell

Multiple Myeloma

NCT07600151 2026-05-20

CONQUISTADOR

Universitätsklinikum Hamburg-Eppendorf

Phase 1/2 Not yet recruiting
220 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT07479979 2026-05-14

Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma

Hoosier Cancer Research Network

Phase 1/2 Recruiting
62 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡